A neuroprotective therapy initiated early would be an ideal treatment option for PD, but a clinically useful neuroprotective drug for PD is not available so far
An experimental ghrelin vaccine, CYT009-GhrQb, was discontinued in 2006 as it did not have the expected effects on weight loss
Confirm composition, sterility status, packaging and storage against the supplied label and documents
M., & Kalogjera, L
Kedua-duanya merupakan 'derivative' kepada Hydroquinone
April 23, 2026 removal from Category 2 FDA removed Semax (along with BPC-157, KPV, MOTs-C, Emideltide / DSIP, Epitalon, and TB-500) from 503A Category 2 effective April 23, 2026 because the underlying nominations were withdrawn